OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian Cancer

February 29th 2024

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr Gopal on the Significance of the EV-302 and CheckMate 901 Trials in mUC

February 29th 2024

Nikhil A. Gopal, MD, discusses how the phase 3 EV-302 and CheckMate 901 trials have advanced the treatment paradigm in metastatic urothelial cancer.

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

February 29th 2024

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer

February 28th 2024

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

Dr Baldonado on the Evolution of Targeted Therapy in NSCLC

February 28th 2024

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.

Dr DeBernardo on an Ovarian Cancer Patient Case Study

February 28th 2024

Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.

Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies

February 28th 2024

Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

February 28th 2024

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Dr Huddart on the FDA Approval of Erdafitinib in FGFR3+ Urothelial Cancer

February 28th 2024

Robert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.

Dr Grajales-Cruz on Benefit With Teclistamab in Select Patients With Relapsed/Refractory Myeloma

February 27th 2024

Ariel Grajales-Cruz, MD, discusses factors associated with benefit from teclistamab in heavily pretreated relapsed/refractory multiple myeloma.

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

February 27th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Dr Merchan on Key Data Supporting Pembrolizumab-Based Regimens in Advanced RCC

February 27th 2024

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRC

February 27th 2024

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant

February 24th 2024

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS

February 24th 2024

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

February 24th 2024

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies

February 24th 2024

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

February 23rd 2024

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

February 23rd 2024

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHD

February 23rd 2024

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.